Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 59 clinical trials
featured
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)

A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (UC)

  • 106 views
  • 08 Nov, 2020
  • 1 location
featured
A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis

A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative

  • 90 views
  • 08 Nov, 2020
  • 1 location
featured
Ulcerative Colitis

Ulcerative Colitis

  • 28 views
  • 08 Nov, 2020
  • 1 location
Adalimumab vs. Conventional Immunosuppression for Uveitis Trial

immunosuppression. Based upon preliminary data, adalimumab, a fully-human, anti-TNFmonoclonal antibody, now US FDA-approved for uveitis treatment, may be a superior corticosteroid-sparing agent than conventional

corticosteroids
prednisone
monoclonal antibodies
small molecule
adalimumab
  • 103 views
  • 24 Jan, 2021
  • 27 locations
Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis

The aim of this study is to determine the efficacy and safety of ADA plus MTX for the treatment in non-infectious pediatric panuveitis.

panuveitis
methotrexate
adalimumab
  • 0 views
  • 26 Oct, 2020
  • 1 location
Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis

with adalimumab 40 mg s.c. eow compared to infliximab 3 mg/kg i.v. every 6 weeks.

adalimumab
infliximab
  • 35 views
  • 07 Nov, 2020
  • 5 locations
UVB-311nm After Initial Slow Response to Adalimumab in Psoriasis

Adalimumab, a fully human anti-tumor necrosis factor (TNF) monoclonal antibody has been approved for the treatment of moderate to severe psoriasis. However, in a portion of cases

adalimumab
phototherapy
tumor necrosis factor alpha
tumor necrosis factor
  • 1 views
  • 07 Nov, 2020
  • 1 location
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis

rheumatoid arthritis. Etanercept is a fusion protein with TNF receptor type II p75 and IgG1 Fc fragment, whereas adalimumab, infliximab, and golimumab are monoclonal antibodies. Certolizumab is a fusion

tnf blocker
rheumatoid arthritis
monoclonal antibodies
il-23
adalimumab
  • 17 views
  • 24 Jan, 2021
  • 26 locations
A Comparative Study Between PF-06410293 and Humira in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

The study will assess the impact of pharmacokinetics (PK), safety and immunogenicity after switches between PF-06410293 and adalimumab and with continuous dosing with adalimumab in combination

adalimumab
methotrexate
humira
  • 124 views
  • 25 Jan, 2021
  • 78 locations
Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS

The primary objective of this randomized controlled clinical trial in a real life setting is to evaluate the cost-utility of limumab monotherapy compared with the combination of adalimumab and a

  • 0 views
  • 22 Jan, 2021
  • 1 location